CAI
NTLA icon

Capital Advisors Inc’s Intellia Therapeutics NTLA Stock Holding History

Capital Advisors Inc’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-203,775
Closed -$4.19M – 312
2024
Q3 		$4.19M Sell
203,775
-107,270
-34% -$2.47M 0.08% 102
2024
Q2 		$6.96M Buy
311,045
+10,392
+3% +$247K 0.14% 97
2024
Q1 		$8.27M Buy
300,653
+15,915
+6% +$442K 0.18% 96
2023
Q4 		$8.68M Buy
284,738
+73,379
+35% +$2.11M 0.19% 95
2023
Q3 		$6.68M Buy
211,359
+14,539
+7% +$564K 0.18% 87
2023
Q2 		$8.03M Buy
196,820
+8,440
+4% +$342K 0.2% 90
2023
Q1 		$7.02M Buy
188,380
+14,724
+8% +$577K 0.19% 90
2022
Q4 		$6.06M Buy
173,656
+1,802
+1% +$85.7K 0.17% 90
2022
Q3 		$9M Buy
171,854
+4,528
+3% +$281K 0.28% 83
2022
Q2 		$8.66M Buy
167,326
+82,405
+97% +$4.18M 0.26% 89
2022
Q1 		$6.17M Buy
84,921
+5,378
+7% +$456K 0.17% 89
2021
Q4 		$9.4M Buy
79,543
+35,298
+80% +$4.42M 0.25% 90
2021
Q3 		$5.93M Buy
44,245
+42,145
+2,007% +$6.38M 0.18% 97
2021
Q2 		$340K Buy
+2,100
New +$164K 0.01% 188
2018
Q4 		– Sell
-110,239
Closed -$3.15M – 191
2018
Q3 		$3.15M Buy
110,239
+2,327
+2% +$67.7K 0.19% 96
2018
Q2 		$2.95M Sell
107,912
-513
-0.5% -$12.4K 0.18% 98
2018
Q1 		$2.29M Buy
108,425
+7,195
+7% +$177K 0.14% 105
2017
Q4 		$1.95M Buy
+101,230
New +$2.34M 0.11% 108

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Advisors Inc's NTLA Position: Q4 2024 in Review

Capital Advisors Inc sold out of Intellia Therapeutics (NTLA) in Q4 2024, closing a stake of 203,775 shares — an estimated $4.19M sold.

Capital Advisors Inc first reported a position in NTLA in Q4 2017 and held it in 18 quarters. The position peaked at $9.4M in Q4 2021. 293 funds tracked by Wall St. Rank hold NTLA as of Q4 2024.

  • Capital Advisors Inc reported no remaining Intellia Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Capital Advisors Inc sold 203,775 Intellia Therapeutics shares in Q4 2024, an estimated $4.19M.
  • Capital Advisors Inc first reported a position in Intellia Therapeutics in Q4 2017 and held it in 18 quarters.
  • Capital Advisors Inc's Intellia Therapeutics position peaked at $9.4M in Q4 2021.
  • 293 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2024.

Based on Capital Advisors Inc's 13F filing for Q4 2024, filed 29 Jan 2025.